Reversal activity of cyclosporin a and its metabolites M1, M17 and M21 in multidrug-resistant cells

International Journal of Cancer

Volumn 71, Issue 5, 1997, Pages 900-906

  Toffoli, Giuseppe ^a   Corona, Giuseppe ^a   Sorio, Roberto ^a   Bertola, Antonella ^a   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZIDOPINE; CISPLATIN; CYCLOSPORIN A; CYCLOSPORIN A METABOLITE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

AFFINITY LABELS; ANTINEOPLASTIC AGENTS; AZIDES; CELL MEMBRANE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DIHYDROPYRIDINES; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; HUMANS; HYDROXYLATION; KINETICS; METHYLATION; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PACLITAXEL; PHOTOCHEMISTRY; TUMOR CELLS, CULTURED;

EID: 0030981148     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970529)71:5<900::AID-IJC32>3.0.CO;2-8     Document Type: Article

References (38)

1. BENET, L.Z. and SCHEINER, L.B., Design and optimization of dosage regimens; pharmacokinetic data (Appendix II). In: A.G. Gilman, L.S. Goodman, T.W. Rall and F. Murad (eds.), The pharmacological basis of therapeutics, pp. 1663-1734, Macmillan, New York (1985).
2. BOIOCCHI, M. and TOFFOLI, G., Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. Europ. J. Cancer, 28A, 1099-1105 (1992).
3. CHARUK, J.H., WONG, P.Y. and REITHMEIER, R.A., Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. Amer. J. Physiol., 269, F31-39 (1995).
4. CHARUK, J.H., Loo, T.W., CLARKE, D.M. and REITHMEIER, R.A., Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A. Amer. J. Physiol., 266, F66-75 (1994).
5. CHEUNG, F., WONG, P.Y., COLE, E., COHEN, Z. and LEVY, G.A., Generation and characterization of cyclosporine metabolites produced in a hepatic microsomal system. Transplant. Proc., 20, 633-636 (1988a).
6. CHEUNG, F., WONG, P.Y., Loo, J., COLE, E.H. and LEVY, G.A., Identification of cyclosporine metabolites in human bile, blood and urine by high-performance liquid chromatography/radioimmunoassay/fast atomic bombardment mass spectroscopy. Transplant Proc., 20, 602-608 (1988b).
7. CHRISTIANS, U. and ZIMMER, K.O., Measurement of cyclosporin A and of four metabolites in whole blood by high-performance liquid chromatosraphy. J. Chromatogr., 413, 121-129 (1987).
8. COPELAND, K.R., THLIVERIS, J.A. and YATSCOFF, R.W., Toxicity of cyclosporine metabolites. Ther. Drug Monit., 12, 525-532 (1990).
9. DREYFUSS, M., HARRI, E., HOFMANN, H., KOBEL, H., PACHE, W. and TSCHERTER, H., Cyclosporin A and C. New metabolites from Trichoderma pohsporum (Link ex Pers.) Rifai. Europ. J. appl. Microbiol., 3, 125-133 (1976).
10. ECHIZEN, H., BRECHT, T., NIEDERGESASS, S., VOGELGESANG, B. and EICHELBAUM, M., The effect of dextro-, levo- and racemic verapamil on atrioventricular conduction in humans. Amer. Heart J., 109, 210-217 (1985).
11. FORD, J.M. and HAIT, W.N., Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199 (1990).
12. FRIDBORG, H., JONSSON, B., NYGREN, P., CSOKA, K., NILSSON, K., OBERG, G., KRISTENSEN, J., BERGH, J., THOLANDER, B., OLSEN, L., JAKOBSON, A. and LARSSON, R., Activity of cyclosporins as resistance modifiers in primary cultures of human haematoloeical and solid tumours. Brit. J. Cancer, 70, 11-17 (1994).
13. GAVERIAUX, C., BOESCH, D., BOELSTERLI, J.J., BOLLINGER, P., EBERLE, M.K., HIESTAND, P., PAYNE, T., TRABER, R., WENGER, R. and LOOR, F., Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Brit. J. Cancer, 60, 867-871 (1989).
14. GOLDSTEIN, L.J. and 13 OTHERS, Expression of a multidrug-resistance gene in human cancers. J. nat Cancer Inst., 81, 116-124 (1989).
15. GRUBER, A., PETERSON, C. and REIZENSTEIN, P., D-verapamil and Lverapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int. J. Cancer, 41, 224-226 (1988).
16. HAUSSERMANN, K., BENZ, B., GEKELER, V., SCHUMACHER, K. and EICHELBAUM, M., Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Europ. J. clin. Pharmacol., 40, 53-59 (1991).
17. HOLLT, V., KOUBA, M., DIETEL, M. and VOGT, G., Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drua transport by P-glycoprotein. Biochem. Pharmacol., 43, 2601-2608 (1992).
18. JULIANO, R.L. and LING, V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. biophys. Acta, 455, 152-162 (1976).
19. LEIER, I., JEDLITSCHKY, G., BUCHHOLZ, U., COLE, S.P., DEELEY, R.G. and KEPPLER, D., The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. biol. Chem., 269, 27807-27810 (1994).
20. MAURER, G. and LEMAIRE, M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc., 18, 25-34 (1986).
21. MAUER, G., Metabolism of cyclosporine. Transplant. Proc., 17, 19-26 (1985).
22. MAURER, G., LOOSLI, H.R., SCHREIER, E. and KELLER, B., Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab. Dispos., 12, 120-126 (1984).
23. MICKISCH, G.H., MERUNO, G.T., AIKEN, P.M., GOTTESMAN, M.M. and PASTAN, I., New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transsenic mice expressing the human MDRI gene. J. Urol., 146, 447-453 (1991).
24. PIRKER, R., KEILHAUER, G., RASCHACK, M., LECHNER, C. and LUDWIG, H., Reversal of multidrue resistance in human KB cell lines by structural analogs of verapamil. Int. Cancer, 45, 916-919 (1990).
25. RODENBURG, C.J., NOOTER, K., HERWEIJER, H., SEYNAEVE, C., OOSTEROM, R., STOTER, G. and VERWEIH, J., Phase-II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal-cell cancer. Ann. Oncol., 2, 305-306 (1991).
26. ROSANO, T.G., FREED, B.M., CERILLI, J. and LEMPERT, N., Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation, 42, 262-267 (1986).
27. SAFA, A.R., Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. nat. Acad. Sci. (Wash.), 85, 7187-7191 (1988).
28. SCHUURHUIS, G.J., BROXTERMAN, H.J., CERVANTES, A., VAN HENNINGEN, T.H., DE LANGE, J.H., BAAK, J.P., PINEDO, H.M. and LANKELMA, J., Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J. nat. Cancer Inst., 81, 1887-1892 (1989).
29. SKOVSGAARD, T., Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res., 38, 4722-4727 (1978).
30. TOFFOLI, G., SORIO, R., GIGANTE, M., CORONA, G. and BOIOCCHI, M., Cyclosporin A as a multidrug-resistant modulator in patients with renal-cell carcinoma treated with teniposide. Brit. J. Cancer 75, 715-721 (1997).
31. TOFFOLL, G., SIMONE, F., CORONA, G., RASCHACK, M., CAPPELLETTO, B., GIGANTE, M. and BOIOCCHI, M., Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol., 50, 1245-1255 (1995).
32. TOFFOLI, G., SIMONE, F., GIGANTE, M. and BOIOCCHI, M., Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug-resistant LoVo cell lines. Biochem. Pharmacol., 48, 1871-1881 (1994).
33. TOFFOLI, G., VIEL, A., TLMIOTTO, L., MAESTRO, R., BISCONTIN, G. and BOIOCCHI, M., Expression of the mdr1 gene in human colorectal carcinomas: relationship with multidrug resistance inferred from analysis of human coloreetal-carcinoma cell lines. Cancer Chemother. Pharmacol., 29, 283-289 (1992).
34. TWENTYMAN, P.R., Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Brit. J. Cancer, 57, 254-258 (1988).
35. VERWEIJ, J., HERWEIJER, H., OOSTEROM, R., VAN DER BURG, M.E., PLANTING, A.S., SEYNAEVE, C., STOTER, G. and NOOTER, K., A phase-II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Brit. J. Cancer, 64, 361-364 (1991).
36. WARNER, E., TOBE, S.W., ANDRULIS, I.L., PEI, Y., TRACHTENBERG, J. and SKORECKI, K.L., Phase-I-II study of vinblastine and oral cyclosporin A in metastatic renal-cell carcinoma. Amer. J. clin. Oncol., 18, 251-256 (1995).
37. YAHANDA, A.M., ADLER, K.M., FISHER, G.A., BROPHY, N.A., HALSEY, J., HARDY, R.I., GOSLAND, M.P., LUM, B.L. and SIKIC, B.I., Phase-I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. clin. Oncol., 10, 1624-1634 (1992).
38. YATSCOFF, R.W., ROSANO, T.G. and BOWERS, L.D., The clinical significance of cyclosporine metabolites. Clin. Biochem., 24, 23-35 (1991).